NCT05716919 2023-10-23
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Machaon Biotherapeutics, Inc.
Phase 1 Unknown
Clinical Trials
15 trialsNCT05690425 2023-07-24
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT05610202 2022-11-09
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05489276 2022-08-05
Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05212584 2022-07-06
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Phase 1 Unknown
NCT05445765 2022-07-06
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Phase 1 Unknown
NCT04632316 2022-06-21
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Glycostem Therapeutics BV
Phase 1/2 Unknown
NCT05020639 2021-09-21
A Study of TQB3820 in Patients With Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05028478 2021-08-31
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Curon Biopharmaceutical (Australia) Co Pty Ltd
Phase 1/2 Unknown
NCT04854681 2021-04-22
Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04412577 2021-04-01
A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04700319 2021-03-08
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT02503033 2020-09-11
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
Hutchmed
Phase 1 Unknown
NCT02828878 2019-11-26
Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation
Cellect Biotechnology
Phase 1/2 Unknown
NCT03344705 2017-11-17
Safety and Efficacy Evaluation of IM19 Cells
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown